Samit Satish Mehta

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.